DNA Vaccine Development and Delivery Methods: Current Status and Future Perspective

Dear Colleagues,

DNA vaccination is one of the most promising methods to handle the current coronavirus pandemic. DNA-based vaccines for COVID-19 are in phase I and II human safety trials from companies such as Zydus Cadila, Anges, etc. Genetic vaccines use one or more of the genes of the virus to activate the host immune response. DNA vaccines instigate cell-mediated immunity, which is effective against many pathogens, compared to standard vaccines that fail to work. A pathogenic epitope is expressed in the host after DNA vaccination, which makes it more effective than the standard vaccine. Moreover, the antigenicity is altered in the manufacturing process of the live attenuated or killed vaccine, which is not observed in the DNA vaccines. The process of construction and manufacturing is very simple with DNA vaccines.

Vaccination for many communicable (including Covid-19) and non-communicable diseases (cancer, atherosclerosis) is still a distant dream in both developed and developing countries. This Special Issue will focus on DNA vaccine development and delivery methods for communicable and non-communicable diseases. Research articles, review articles, and short communication based on the current status and future perspectives of the DNA vaccination development are invited.

Dr. Muthu Narayanan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• DNA vaccine
• Cell-mediated immunity
• Communicable and non-communicable disease
• Delivery methods